Selectivity of NSAIDs for COX-2 and cardiovascular outcome

Br J Clin Pharmacol. 2006 Aug;62(2):243-5. doi: 10.1111/j.1365-2125.2006.02620.x.

Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) with increased selectivity for the cyclooxygenase-2 (COX-2) isoform reduce gastrotoxicity but may increase adverse cardiovascular events.

Methods: We searched the literature for studies that reported the odds ratio (OR) for such events following exposure to NSAIDs.

Results: For studies comparing NSAID use with no use, increased COX-2 selectivity was significantly related to cardiovascular risk (log OR) amongst observational studies (R = -0.34, P < 0.001) and randomized controlled trials (RCTs) (R = -0.56, P < 0.001). For studies comparing NSAIDs, difference in selectivity was related to risk for observational studies (R = -0.28, P = 0.005) but not for RCTs (R = -0.23, P = 0.15).

Conclusions: Although increased COX-2 selectivity may reduce gastrotoxicity, this may be at the cost of increasing cardiovascular risk.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Cardiovascular Diseases / chemically induced*
  • Cyclooxygenase 2 / metabolism*
  • Humans
  • Research Design
  • Risk Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2